GlassScriptPhysician profile
Sion Jasmine
NPI 1023512852
$5,289.83
in general payments reported to CMS, 2019-2025
22 companies · $2,344 in 2025
The $2,344 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $116 · 2023: $835 · 2024: $1,995 · 2025: $2,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,995 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,995.03 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $807.49 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $757.06 | 2023-2025 | Tremfya |
| Abbvie INC. | $620.73 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $620.42 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $419.97 | 2023-2025 | Sotyktu |
| Ucb, INC. | $391.73 | 2023-2025 | Bimzelx |
| Genzyme Corporation | $302.46 | 2023-2024 | |
| Galderma Laboratories, L.P. | $219.98 | 2024-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $192.60 | 2023-2025 | Adbry |
| Dermavant Sciences, INC. | $179.22 | 2024 | Vtama |
| Lilly USA, LLC | $120.50 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $120.41 | 2023-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $112.73 | 2025 | |
| Pfizer INC. | $108.68 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $80.68 | 2023-2024 | Dupixent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $52.24 | 2025 | Sofdra |
| Organon LLC | $46.98 | 2024-2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.36 | 2024 | Spevigo |
| Janssen Scientific Affairs, LLC | $32.37 | 2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.55 | 2024-2025 | Cabtreo, Jublia, Targretin |
| Sun Pharmaceutical Industries INC. | $18.72 | 2025 | |
| Paratek Pharmaceuticals, INC. | $16.95 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sion Jasmine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.